PET imagining in Alzheimer’s disease

Purpose. The purpose of this article is to explore the potential of positron emission tomography (PET) in early diagnosis of Alzheimer's disease (AD), monitoring of disease progression and assessment of treatment effectiveness. And also, to become familiar with advantages and disadvantages of a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ukraïnsʹkij žurnal vìjsʹkovoï medicini 2023-12, Vol.4 (4), p.45-54
Hauptverfasser: Korol, P. O., Lukashenko, M. S., Shcherbina, O. V., Murashko, V. О., Ivchuk, V. P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose. The purpose of this article is to explore the potential of positron emission tomography (PET) in early diagnosis of Alzheimer's disease (AD), monitoring of disease progression and assessment of treatment effectiveness. And also, to become familiar with advantages and disadvantages of application of various radiopharmaceuticals. Materials and methods. The material for the study was the scientific results of publications in professional scientific journals of the leading countries of the world of scientific and clinical activity over the past 10 years on the clinical significance of hybrid radiation imaging methods in the diagnosis and treatment of patients with AD. The study involved the use of PET radiation imaging methods in Alzheimer's disease. Results. The efficacy of PET at different stages of AD has been demonstrated. The advantages and disadvantages of using different PET techniques and different radiopharmaceuticals are discussed. PET, unlike other biomarkers, is able to assess the prevalence of lesions, evaluate progression and make a prediction of the further course of the disease. Conclusions. Positron emission tomography in patients with AD is an effective diagnostic technique that can be used at different stages from the prodromal period in the form of mild cognitive impairment to assessing the progression or effectiveness of treatment in numerous clinical trials.
ISSN:2708-6615
2708-6623
DOI:10.46847/ujmm.2023.4(4)-045